CN114504097A - Umami peptide, composition containing same and application - Google Patents
Umami peptide, composition containing same and application Download PDFInfo
- Publication number
- CN114504097A CN114504097A CN202210408389.8A CN202210408389A CN114504097A CN 114504097 A CN114504097 A CN 114504097A CN 202210408389 A CN202210408389 A CN 202210408389A CN 114504097 A CN114504097 A CN 114504097A
- Authority
- CN
- China
- Prior art keywords
- peptide
- umami
- salt
- umami peptide
- salty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 100
- 235000019583 umami taste Nutrition 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 239000011780 sodium chloride Substances 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 51
- 239000000654 additive Substances 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 13
- 230000000996 additive effect Effects 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 235000019643 salty taste Nutrition 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 239000011833 salt mixture Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000004278 EU approved seasoning Substances 0.000 claims description 3
- 235000011194 food seasoning agent Nutrition 0.000 claims description 3
- 235000008446 instant noodles Nutrition 0.000 claims description 3
- 235000013622 meat product Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 235000014109 instant soup Nutrition 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 18
- 108090000790 Enzymes Proteins 0.000 abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000030883 sensory perception of salty taste Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 33
- 235000019640 taste Nutrition 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- JYGRAOYMDDFOSM-FQJIPJFPSA-N (4s)-4-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]propanoyl]amino]butanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentano Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN JYGRAOYMDDFOSM-FQJIPJFPSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108010053500 delicious peptide Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019600 saltiness Nutrition 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 159000000000 sodium salts Chemical group 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002173 cutting fluid Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 tetrafluoroborate Chemical compound 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
- A23L27/45—Salt substitutes completely devoid of sodium chloride
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Seasonings (AREA)
Abstract
The present invention relates to an umami peptide, compositions comprising the same and uses thereof. The sequence of the umami peptide provided by the application is TPLVDR. The application provides an umami peptide with ACE enzyme inhibitory action, has better salty taste perception, can replace partial sodium chloride as the substitute salt, can reach and subtract the purpose that salt does not reduce salt, owing to have ACE enzyme inhibitory action, can play the effect of alleviating to cardiovascular disease simultaneously.
Description
Technical Field
The invention belongs to the field of salt substitutes, and particularly relates to umami peptide, a composition containing the umami peptide and application of the umami peptide.
Background
Salty taste is the first of five tastes and is the favorite taste of people. At present, most of edible salt used by people is sodium salt, and excessive intake of sodium can cause hypertension, increase the incidence of cardiovascular and cerebrovascular diseases such as heart disease and stroke, but the reduction of the use of edible salt can greatly influence the flavor of food.
The data show that the umami peptide has the function of increasing the saltiness, so the proper use of the umami peptide as a food additive can achieve the functions of reducing the salt and not reducing the saltiness. And the food additive is widely applied to instant noodles, meat products, chicken essence and seasonings, puffed and leisure foods, quick-frozen foods and the like.
There is a need in the art to develop a umami peptide with salt-substituting effect, which can improve the risk of hypertension or angiosclerosis diseases caused by sodium salt.
Disclosure of Invention
In view of the deficiencies of the prior art, it is an object of the present application to provide an umami peptide having the sequence TPLVDR.
The umami peptide provided by the application has better salty taste perception, can be used as a substitute salt to replace partial sodium chloride, and can achieve the purpose of reducing salt without reducing salty taste. In addition, the umami peptide provided by the application also has a certain ACE enzyme inhibition effect.
ACE enzyme is key to cardiovascular therapy and plays an important role in regulating blood pressure through the renin-angiotensin system. ACE enzyme converts angiotensin i to angiotensin ii, which is a vasoconstrictor and inactivates bradykinin, a potent vasodilator, leading to elevated blood pressure.
The umami peptide provided by the application has obvious ACE enzyme inhibitory activity, and the long-term consumption of the umami peptide containing ACE enzyme inhibitory activity can obviously reduce blood pressure and relieve cardiovascular and cerebrovascular diseases.
Namely, the umami peptide provided by the application not only can replace part of sodium chloride, achieve the effects of reducing salt and not reducing salt, reduce the intake of sodium chloride and the incidence of cardiovascular diseases, but also can inhibit ACE enzyme, reduce the incidence probability of cardiovascular diseases caused by sodium chloride which is not replaced, or improve the cardiovascular problems of a user.
Another object of the present application is to provide a use of the umami peptide according to one of the objects, as any one or a combination of at least two of health product additives and health food additives;
preferably, the health care product comprises a health food for inhibiting hypertension and/or a health food for softening blood vessels.
Preferably, the umami peptide is used at a concentration of 0.28-0.44 mg/mL, such as 0.30mg/mL, 0.33mg/mL, 0.35mg/mL, 0.37mg/mL, 0.39mg/mL, 0.40mg/mL, 0.42mg/mL, and the like.
It is a further object of the present application to provide a salt substitute mixture comprising the umami peptide of one of the objects and a second peptide; the sequence of the second peptide is AEINKILGN.
Preferably, the mixing molar ratio of the umami peptide and the second peptide is 1: 9-2: 3 (for example, 2:9, 1:3, 4:9, 5:9, etc.), and preferably 3: 7-3: 2.
The taste (such as bitter) that the umami peptide concentration of this application purpose is too high slightly to take bad taste, has restricted the addition of umami peptide, the umami peptide that this application provided with as substituting salt mixture after the second peptide mixes, can improve its sodium chloride's substitute quantity, can also keep ACE enzyme's inhibitory effect simultaneously.
A fourth object of the present application is to provide the use of a salt substitute mixture according to the third object as a salty taste additive.
Preferably, the salt-substituting mixture is used as a salty additive for instant noodles, a salty additive for meat products, a salty additive for puffed and snack foods, a salty additive for quick-frozen foods, a salty additive for instant soups, a salty additive for thick soups or a salty additive for low-sodium seasonings.
Alternatively, the salt substitute mixture is used for a health food for inhibiting hypertension and/or a health food for softening blood vessels.
Preferably, the salt-substituting mixture is used in a concentration of 77-244 mg of the third or 5 salt-substituting mixture added per 100mL of water.
The fifth purpose of the application is to provide a salty composition, which comprises 1.65-1.80 parts by weight of common salt and 1 part of salt substitute mixture as the third purpose.
It is a further object of the present application to provide a umami enhancing peptide for enhancing saltiness, which has the sequence AEINKILGN.
Preferably, the refreshing peptide is used as any one of or a combination of at least two of a health product additive and a health food additive.
Preferably, the freshening peptides are used as a health food for inhibiting hypertension and/or a health food for softening blood vessels.
Preferably, the usage concentration of the freshness-increasing peptide is 0.50-2.00 mg/mL.
In umami peptides, T is threonine (Thr), P is proline (Pro), L is leucine (Leu), V is valine (Val), D is aspartic acid (Asp), R is arginine (Arg); a is alanine (Ala), E is glutamic acid (Glu), I is isoleucine (Ile), N is asparagine (Asn), K is lysine (Lys), and G is glycine (Gly).
It is noted that the umami peptide of sequence TPLVDR and the umami peptide of sequence AEINKILGN provided herein can be synthesized by standard methods or by several synthetic routes well known to those skilled in the art of peptide synthesis to prepare the short chain peptides of the invention.
Illustratively, the umami peptide of sequence TPLVDR and the umami peptide of sequence AEINKILGN can be synthesized using the methods described below and conventional techniques known to those skilled in the art of peptide synthesis or variations thereof as understood by those skilled in the art.
If a solid phase method is adopted to synthesize the delicious peptide or the flavor enhancing peptide, the Wang resin is taken as a solid phase carrier, the resin is soaked and swelled and then washed, proline and a condensing agent protected by Fmoc are added according to the sequence of the target peptide to carry out deprotection and condensation reaction of amino, the deprotection-condensation process is repeated until all amino acids are connected, and the target peptide is obtained after the resin is cut.
Exemplary of these are the umami peptide TPLVDR (Thr-Pro-Leu-Val-Asp-Arg), which can be synthesized by the following solid phase method:
if fresh peptide is synthesized by adopting a solid phase method, fmoc-Arg (pbf) -queen resin is soaked, swelled and washed, reacted with a decapping solution (piperidine + N, N-dimethylformamide) for 15min and then washed to remove fmoc, then fmoc-Asp-OH amino acid is added, TBTU (O-benzotriazole-N, N, N ', N' -tetramethylurea tetrafluoroborate) is used as a condensing agent, N, N-diisopropylethylamine and a solvent N, N-dimethylformamide are used as alkali reagents for 30min of condensation reaction, and then washing is carried out; then adding a decapping solution (piperidine + N, N-dimethylformamide) to react and remove fmoc, and washing; repeating the steps to graft Val, Leu, Pro to Thr in sequence, finally performing a cutting reaction on the trifluoroacetic acid cutting fluid and the resin condensed with the amino acid, and adding ether into the filtrate to precipitate the polypeptide to obtain a crude product; and then purifying the crude product by using ion exchange resin, converting trifluoroacetate into acetate, and freeze-drying to obtain a high-purity product.
Compared with the prior art, the method has the following beneficial effects:
(1) the application provides an umami peptide with ACE enzyme inhibitory action, has better salty taste perception, can replace partial sodium chloride as the substitute salt, can reach and subtract the purpose that salt does not reduce salt, owing to have ACE enzyme inhibitory action, can play the effect of alleviating to cardiovascular disease simultaneously.
(2) In the salty taste composition provided by the application, the delicious peptide can show bad taste (such as bitter taste) when being excessively concentrated, the addition amount of the delicious peptide is limited, and the delicious peptide provided by the application and the second peptide (flavor enhancing peptide) are mixed to be used as a salt substitute mixture, so that the substitution amount of sodium chloride can be increased, and the inhibiting effect of ACE enzyme can be kept.
Drawings
FIG. 1 is an HPLC chromatogram of umami peptide TPLVDR;
FIG. 2 is a graph of secondary mass spectrometry analysis of umami peptide TPLVDR;
fig. 3 is an HPLC chromatogram of the umami peptide AEINKILGN;
fig. 4 is a secondary mass spectrometry analysis of the freshener peptide AEINKILGN.
Detailed Description
The technical solution of the present invention is further explained with reference to the following embodiments, but it should be noted that the embodiments are only an embodiment and explanation of the technical solution of the present invention, and should not be construed as a limitation to the scope of the present invention.
The reagents and instruments used in the examples are commercially available and the detection methods are conventional methods well known in the art.
Synthesis example 1
The Nanjing-derived peptide Biotechnology Ltd was entrusted with the synthesis of the umami peptide TPLVDR.
The purity of the synthesized TPLVDR was checked by HPLC (equipment model Agilent 1100), and as shown in fig. 1 (fig. 1 is an HPLC chromatogram of umami peptide TPLVDR), the purity was 98.72%.
The molecular weight and structure were determined by HPLC-MS (equipment model AB SCIEX X500R Q-TOF) and as shown in FIG. 2 (FIG. 2 is a secondary mass spectrum analysis chart of umami peptide TPLVDR), the molecular weight was 699.39 Da and the structure was H-Thr-Pro-Leu-Val-Asp-Arg-OH.
Synthesis example 2
The peptide AEINKILGN was synthesized by Nanjing peptide Biotechnology Ltd.
The purity of the synthesized AEINKILGN was determined by HPLC (equipment model Agilent 1100), and as shown in fig. 3 (HPLC chromatogram of zenith peptide AEINKILGN in fig. 3), the purity was 98.96%.
The molecular weight and structure were determined by HPLC-MS/MS (equipment model AB SCIEX X500R Q-TOF), and as shown in FIG. 4 (FIG. 4 is a secondary mass spectrometry diagram of the peptide AEINKILGN), the molecular weight was 970.54Da and the structure was H-Ala-Glu-Ile-Asn-Lys-Ile-Leu-Gly-Asn-OH.
And (3) flavor analysis:
14 sensory evaluation panelists who were healthy (8 females and 6 males, aged 24 to 30 years) and had sensory evaluation experience were recruited from the laboratory. Firstly, taste training for 2 weeks is carried out on evaluation team members, and the training contents are as follows: and presenting the aqueous solutions of the six sour, sweet, bitter, salty, fresh and astringent taste markers to a sensory evaluator. The standards are food grade sucrose (50.00 g/L and 10.00 g/L), citric acid (5.00 g/L and 1.00 g/L), sodium chloride (15.00 g/L and 3.00 g/L), sodium glutamate (20.00 g/L and 4.00 g/L), quinine (0.006 g/L and 1.20 g/L) and tea polyphenols (5.00 g/L and 1.00 g/L), respectively. Screening is carried out according to whether the difference between the two concentrations can be correctly judged by an evaluator.
Fresh taste peptide TPLVDR and freshness-increasing peptide AEINKILGN are respectively prepared into 5g/L evaluation solutions (the solvent is pure water), the evaluation solutions are subjected to gradient dilution by pure water according to the proportion of 1:1, the concentrations are 1250.00 mug/mL, 900.00 mug/mL, 800.00 mug/mL, 700.00 mug/mL, 625.00 mug/mL, 450.00 mug/mL, 312.50 mug/mL, 156.25 mug/mL, 78.125 mug/mL and 39.0625 mug/mL respectively, and then the evaluation solutions are presented to sensory evaluators for taste sorting of the taste intensities. When the difference in taste between a certain dilution level of the solution and the blank is not recognized by any one of the evaluators, the dilution concentration of a sample is recorded as the threshold value of the sample in the blank solution (pure water) in the experiment.
The threshold value measurement experiment was repeated 5 times, and the threshold value results were averaged to obtain the threshold value of the sample in the blank solution (pure water).
According to determination, the threshold value of the umami peptide TPLVDR is 88.3883 mug/mL, and the threshold value of the freshness-increasing peptide AEINKILGN is 707.1068 mug/mL.
Example 1
A salt substitute mixture comprising 1mol of umami peptide TPLVDR and 9mol of umami peptide AEINKILGN.
Example 2
A salt substitute mixture comprising 3mol of umami peptide TPLVDR and 7mol of umami peptide AEINKILGN.
Example 3
A salt substitute mixture comprising 1mol of umami peptide TPLVDR and 4mol of umami peptide AEINKILGN.
Example 4
A salt substitute mixture comprising 2mol of umami peptide TPLVDR and 3mol of umami peptide AEINKILGN.
Salt substitute quantity test:
(1) preparing a saline solution to be detected:
the salt substitute mixture provided in the example was dispersed in pure water together with sodium chloride to obtain a salty solution to be measured. In the salty solution, the content of sodium chloride was 0.3wt%, and the addition amount of the substitute salt mixture was 2 mmol/L.
Dispersing the umami peptide TPLVDR and sodium chloride in pure water to obtain the umami peptide solution to be detected. In the umami peptide solution, the content of sodium chloride is 0.3wt%, and the addition amount of the umami peptide TPLVDR is 0.6 mmol/L.
Dispersing the flavor enhancing peptide AEINKILGN and sodium chloride in pure water to obtain the flavor enhancing peptide solution to be detected. In the umami peptide solution, the content of sodium chloride is 0.3wt%, and the addition amount of the flavor enhancing peptide AEINKILGN is 2 mmol/L.
(2) Preparing sodium chloride solution with gradient concentrations of 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt% and 0.5wt% as standard solution, selecting an evaluator of 'taste analysis' to taste the salinity of the salty solution to be detected, judging the concentration of the standard solution close to the salinity of the salty solution to be detected, and calculating the average value of the concentration and marking as X (wt%); the salt substitution amount A is calculated by the following formula.
A%=(X-0.3wt%)/X
The results are shown in Table 1.
Assay for ACE converting enzyme inhibitory activity test:
(1) identification of antihypertensive activity:
preparation of saline BBS buffer (containing 0.9% dNaCl): transferring 100mL of 0.5M standard boric acid buffer solution (0.1M, pH 8.0) into a 500mL quantitative bottle, adding 0.015mol of NaCl solid, namely 0.8766g (the relative molecular mass is 58.44 g/mL), adding deionized water for constant volume, and storing at 0 ℃;
preparing an ACE enzyme (0.1U/mL) solution: dissolving 0.1U of ACE enzyme in 1mL of salt-containing BBS buffer solution (containing 0.03 MNaCl), and storing at-20 ℃ for later use;
preparing a HHL (equacyl-histidyl-leucine) solution: dissolving 5mg in 10mL of salt-containing BBS buffer solution to prepare a HHL solution of 2.5mg/mL, and storing at-20 ℃;
preparing a peptide sample: preparing the salt-substituting mixture, the umami peptide TPLVDR and the flavor enhancing peptide AEINKILGN provided by the embodiments 1-4 into 2mmol/L solutions (the solvent is BBS buffer solution containing 0.9% NaCl) respectively to be used as peptide samples;
and (3) testing: mixing 20 μ L of peptide sample with 100 μ L of HHL solution, preheating to 37 deg.C, adding 20 μ L of LACE converting enzyme solution, performing metal bath at 37 deg.C for 2 hr, adding 100 μ L of hydrochloric acid to inactivate when the temperature is returned to room temperature, and analyzing the reaction solution with 0.45 μm organic filter membrane.
In order to reduce errors, the reaction group is provided with 2 times of repeated experiments, and each group is provided with a blank group (20 mu L of peptide sample is taken to be mixed with 100 mu L of HHL solution and preheated to 37 ℃, 20 mu L of salt-containing BBS buffer solution is added, metal bath is carried out for 2h at 37 ℃, 100 mu L of hydrochloric acid is added for inactivation when the temperature is recovered to the room temperature, the reaction solution passes through a 0.45 mu M organic filter membrane and then is subjected to sample injection analysis), and in order to ensure the rigor of the experiment, a control group is made (20 mu L of salt-containing BBS buffer solution is taken to be mixed with 100 mu L of HHL solution and preheated to 37 ℃, 20 mu L of LACE converting enzyme solution is added, metal bath is carried out for 2h at 37 ℃, 100 mu L of hydrochloric acid is added for inactivation when the temperature is recovered to the room temperature, and the reaction solution passes through a 0.45 mu M organic filter membrane and then is subjected to sample injection analysis).
The test results are shown in Table 1.
TABLE 1
Examples of the invention | Amount of salt substitute | Inhibition rate |
Example 1 | 15 | 81.0% |
Example 2 | 18 | 80.3% |
Example 3 | 20 | 81.1% |
Example 4 | 22 | 80.4% |
|
8 | 77.4% |
Brightness enhancing |
5 | 74.4% |
From table 1, the umami peptide TPLVDR provided by the application has a high ACE inhibition rate, and is matched with the freshening peptide AEINKILGN, so that the substitution amount of sodium chloride can be increased, and the inhibition effect of ACE enzyme can be maintained.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. An umami peptide, wherein the sequence of the umami peptide is TPLVDR.
2. The use of the umami peptide of claim 1 as any one of or a combination of at least two of a nutraceutical additive, a health food additive;
the health care product comprises a health food for inhibiting hypertension and/or a health food for softening blood vessels.
3. The use of claim 2, wherein the umami peptide is used at a concentration of 0.28-0.44 mg/mL.
4. A primary salt mixture comprising the umami peptide of claim 1 and a second peptide;
the sequence of the second peptide is AEINKILGN.
5. The salt-substituting mixture of claim 4, wherein the mixing molar ratio of the umami peptide and the second peptide in claim 1 is 1: 9-2: 3.
6. Use of a salt substitute mixture according to claim 4 or 5 as a salty taste additive.
7. Use of the salt-substituting mixture according to claim 6 as a salty additive for instant noodles, for meat products, for puffed and snack foods, for quick-frozen foods, for instant soups or for low-sodium seasonings;
alternatively, the salt substitute mixture is used for a health food for inhibiting hypertension and/or a health food for softening blood vessels.
8. Use of a primary salt mixture according to claim 6 in a concentration of 77-244 mg per 100mL water of a primary salt mixture according to claim 4 or 5.
9. A salty composition comprising 1.65 to 1.80 parts by weight of common salt and 1 part of the salt substitute mixture according to claim 4 or 5.
10. A umami enhancing peptide for enhancing salty taste, wherein the sequence of the umami enhancing peptide is AEINKILGN.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210408389.8A CN114504097B (en) | 2022-04-19 | 2022-04-19 | Umami peptide, composition containing same and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210408389.8A CN114504097B (en) | 2022-04-19 | 2022-04-19 | Umami peptide, composition containing same and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114504097A true CN114504097A (en) | 2022-05-17 |
CN114504097B CN114504097B (en) | 2022-08-19 |
Family
ID=81555417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210408389.8A Expired - Fee Related CN114504097B (en) | 2022-04-19 | 2022-04-19 | Umami peptide, composition containing same and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114504097B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116391846A (en) * | 2023-04-27 | 2023-07-07 | 安琪酵母股份有限公司 | Sweet taste enhancing peptide of steviol glycoside, composition containing sweet taste enhancing peptide and application of sweet taste enhancing peptide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143488A1 (en) * | 2007-12-03 | 2009-06-04 | Laurence Trinnaman | Peptides imparting umami, salt, dairy and bitter flavor |
JP2010090061A (en) * | 2008-10-08 | 2010-04-22 | Kohjin Co Ltd | New peptide composition having body-imparting function |
CN106901311A (en) * | 2015-12-22 | 2017-06-30 | 丰益(上海)生物技术研发中心有限公司 | Flavor peptide and application |
CN110776556A (en) * | 2019-10-21 | 2020-02-11 | 宁波大学 | Peptide with ACE (angiotensin converting enzyme) inhibition and antioxidant activities as well as preparation method and application thereof |
CN111961115A (en) * | 2020-07-27 | 2020-11-20 | 宁波大学 | Umami peptide and preparation method and application thereof |
-
2022
- 2022-04-19 CN CN202210408389.8A patent/CN114504097B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143488A1 (en) * | 2007-12-03 | 2009-06-04 | Laurence Trinnaman | Peptides imparting umami, salt, dairy and bitter flavor |
JP2010090061A (en) * | 2008-10-08 | 2010-04-22 | Kohjin Co Ltd | New peptide composition having body-imparting function |
CN106901311A (en) * | 2015-12-22 | 2017-06-30 | 丰益(上海)生物技术研发中心有限公司 | Flavor peptide and application |
CN110776556A (en) * | 2019-10-21 | 2020-02-11 | 宁波大学 | Peptide with ACE (angiotensin converting enzyme) inhibition and antioxidant activities as well as preparation method and application thereof |
CN111961115A (en) * | 2020-07-27 | 2020-11-20 | 宁波大学 | Umami peptide and preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
张佳汇等: "鲜味肽介绍及其在调味料中应用的探讨", 《食品工业》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116391846A (en) * | 2023-04-27 | 2023-07-07 | 安琪酵母股份有限公司 | Sweet taste enhancing peptide of steviol glycoside, composition containing sweet taste enhancing peptide and application of sweet taste enhancing peptide |
CN116391846B (en) * | 2023-04-27 | 2024-06-07 | 安琪酵母股份有限公司 | Sweet taste enhancing peptide of steviol glycoside, composition containing sweet taste enhancing peptide and application of sweet taste enhancing peptide |
Also Published As
Publication number | Publication date |
---|---|
CN114504097B (en) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhuang et al. | Sequence, taste and umami-enhancing effect of the peptides separated from soy sauce | |
Nishimura et al. | Umami compounds enhance the intensity of retronasal sensation of aromas from model chicken soups | |
EP2253227B1 (en) | Saltiness-strengthening agent and food or drink containing the same | |
CN111961115B (en) | Umami peptide and preparation method and application thereof | |
KR20080005552A (en) | Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride produced by the process | |
CN114504097B (en) | Umami peptide, composition containing same and application | |
JP4128892B2 (en) | Method for enhancing salty taste of food and drink and seasoning used therefor | |
CN102603870A (en) | Taste peptide as well as preparation method and application thereof | |
CN108623660B (en) | Delicious tetradecapeptide, Maillard reaction product and application thereof | |
Feng et al. | Exploring novel Kokumi peptides in Agaricus bisporus: selection, identification, and tasting mechanism investigation through sensory evaluation and computer simulation analysis | |
CN109090559B (en) | Umami dipeptide and application thereof as seasoning | |
CN106901311B (en) | Flavor-developing peptide and application | |
CN108634280B (en) | Delicious hexapeptide and application thereof | |
CN111537675A (en) | Method for determining key taste substances of grifola frondosa | |
EP3417723A1 (en) | Composition having rich-taste imparting function | |
CN113080426B (en) | Flavor development peptide and preparation method thereof | |
CN116391846B (en) | Sweet taste enhancing peptide of steviol glycoside, composition containing sweet taste enhancing peptide and application of sweet taste enhancing peptide | |
CN116473209B (en) | Sweet taste enhancing composition, sweet taste enhancing peptide, sweet taste enhancing auxiliary peptide and application of mogroside | |
CN109170803B (en) | Chicken flavor enhancing peptide and preparation method and application thereof | |
KR100415267B1 (en) | Two stage salted-fermented anchovy sauce and method for production therof | |
CN107325156B (en) | Polypeptide with taste development property and polypeptide lipidization modification product | |
CN117736263A (en) | Salty taste enhancing peptide, salty taste enhancing compound containing salty taste enhancing peptide and application of salty taste enhancing compound | |
CN103936831A (en) | Globefish flavoring peptides, its preparation method and its application | |
TWI407916B (en) | Kokumi-imparting agent | |
CN110305192B (en) | Delicate flavor polypeptide and flavor composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Yuyu Inventor after: Sun Baoguo Inventor after: Liang Li Inventor after: Zhang Jincheng Inventor before: Zhang Yuyu |
|
CB03 | Change of inventor or designer information | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220819 |
|
CF01 | Termination of patent right due to non-payment of annual fee |